Want to see HK:8622 full AI Analyst Report?

Huakang Biomedical Holdings Company Limited (8622) Price & Analysis

0 Followers

8622 Stock Chart & Stats

HK$0.42

HK$0.01(7.32%)

At close: Jan 09 4:00 PM EST

HK$0.42

HK$0.01(7.32%)

Day’s Range― - ―

52-Week RangeHK$0.15 - HK$0.75

Previous CloseN/A

Volume952.00K

Average Volume (3M)2.14M

Market Cap

HK$91.75M

Enterprise ValueHK$68.87M

Total Cash (Recent Filing)HK$41.96M

Total Debt (Recent Filing)HK$4.96M

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding515,472,000

10 Day Avg. Volume1,472,000

30 Day Avg. Volume2,141,866

Financial Highlights & Ratios

PEG Ratio-2.40

Price to Book (P/B)3.83

Price to Sales (P/S)6.93

P/FCF Ratio-59.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative LeverageVery low debt-to-equity (~0.10 in 2025) provides structural financial flexibility, lowering near-term refinancing risk and preserving optionality to fund operations, R&D, or acquisitions. This durability matters if cash generation is volatile or capital needs arise.

High Gross MarginsSustained ~63% gross margins point to strong product-level economics and pricing power in the core business. High gross margin gives room to absorb SG&A and R&D and supports potential margin recovery if operating leverage improves with scale or cost discipline.

Modest Revenue GrowthConsistent, positive top-line growth (modest year-over-year gains) indicates ongoing customer demand and market traction. Over a 2–6 month horizon, steady revenue growth supports the case for operational scaling and provides a basis for eventual margin improvement.

Bears Say

Negative Cash FlowTwo consecutive years of negative operating and free cash flow indicate the business consumes cash to run, increasing reliance on balance-sheet reserves or external financing. This structural cash burn raises funding and execution risk over the medium term.

Large Operating LossesDeep negative operating margins (~-28%) show core operations do not cover fixed and overhead costs. Persistent wide losses reduce ability to reinvest, complicate path to profitability, and mean operational improvements must be substantial to achieve sustainable earnings.

Erosion Of Equity & Negative ROENegative ROE and declining equity reflect erosion of shareholder capital from sustained losses. Over the medium term this weakens the balance-sheet buffer, can constrain strategic choices, and may force dilutive financing if cash burn continues.

8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?

Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.15 and its highest was HK$0.75 in the past 12 months.

What is Huakang Biomedical Holdings Company Limited’s market cap?

Huakang Biomedical Holdings Company Limited’s market cap is HK$91.75M.

When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?

Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Aug 11, 2026 which is in 5 days.

How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?

Huakang Biomedical Holdings Company Limited released its earnings results on Mar 27, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.006.

Is Huakang Biomedical Holdings Company Limited overvalued?

According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Huakang Biomedical Holdings Company Limited pay dividends?

Huakang Biomedical Holdings Company Limited does not currently pay dividends.

What is Huakang Biomedical Holdings Company Limited’s EPS estimate?

Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Huakang Biomedical Holdings Company Limited have?

Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.

What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?

Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.

Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?

Currently, no hedge funds are holding shares in HK:8622

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Huakang Biomedical Holdings Company Limited Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

6.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.